Thinkzone Network: Taizhou Life Sciences Enterprises -1
Taizhou, as the birthplace of China's joint-stock economy, is one of the most developed places in China. By 2020, Taizhou has 50 public listed companies, ranking 4th in China, and private companies contribute more than 95% of the city’s GDP. Taizhou encourages innovation and entrepreneurship, and equips manufacturing and pharmaceutical industries as two engines to form seven-hundred-billion-industry clusters including automobiles, chemistry, and life sciences.
Taizhou is the largest manufacturing and national export base of APIs. It has formed a mature supply chain and ecosystem for antibiotics, cancer drugs, hormones drugs, and cephalosporins. Among 114 life sciences companies in Taizhou and 10 are public listed.
Founded in 1998, JIUZHOU is a leading manufacturer of API and CDMO in China. It is in the leading place of technology and scale in the field of small molecule drugs. The core technologies include chiral catalysis, fluorine chemistry, continuous reaction, and photochemical technology.
JIUZHOU Pharmaceutical's manufacturing bases are in Taizhou, Suzhou, and Yancheng, and its research and development centers are in Hangzhou, Denmark, and the United States. After acquiring the Suzhou Novartis CMO factory in 2019, JIUZHOU has accelerated its transformation and upgrading to CDMO and is currently cooperating with Novartis on heart failure related products.
As a company that has multiple R&D centers overseas and has achieved cross-border acquisitions, JIUZHOU's strategy is to invest in the ecosystem of innovative pharmaceutical companies, with a long-term expectation on the future development.
HISOAR was established in 1966. It has more than 10 subsidiaries, and more than 70% of its products are exported overseas. The pharmaceutical sector includes intermediates, API (including human and veterinary drugs), pharmaceutical manufacturing and international pharmaceutical CDMO/CMO services. HISOAR’s products cover anti-infection, cardiovascular, mental illness, metabolism, immunity, and other fields. And it is the world's largest manufacturer of clindamycin.
HISOAR has its own USD and RMB fund, and mainly invests in the healthcare field. Traditional medicine, digital medicine, digital diagnosis, healthcare informatization, healthcare services, medical devices, chemical materials, are all HISOAR’s interested fields. The first choice is to invest in relatively mature companies that are highly integrated with their existing business sectors.
Ausun is one of the fastest-growing manufacturing companies in China. It was established in 2012 and successfully went public in only 5 years. Talents, innovation and technology are the three core drivers of Ausun, and it invests more than 12% in R&D every year. Ausun's businesses are mainly intermediates, APIs, preparations, and new drugs, with technology strengths in liver diseases, respiratory system, cardiovascular and cerebrovascular system, fluorine products, prostaglandins, antibacterial products, and cancer products. The products have passed EU GMP, US FDA and many certifications. As a local API company, 90% of Ausun's market is outside of China.
Due to the surge demand of the epidemic, Ausun plans to raise a fund (350 million yuan maximum) for the construction of APIs and key pharmaceutical intermediates manufacturing bases.
In terms of investment, Ausun takes an open attitude. Ausun is willing to invest in new drugs and startups with promising technologies in line with Ausun’s products.